Next Article in Journal
Bacillus Calmette–Guérin Immunotherapy for Cancer
Next Article in Special Issue
Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2
Previous Article in Journal
Thermostable, Dissolvable Buccal Film Rotavirus Vaccine Is Highly Effective in Neonatal Gnotobiotic Pig Challenge Model
Previous Article in Special Issue
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Article

The Safe Baculovirus-Based PrM/E DNA Vaccine Protected Fetuses against Zika Virus in A129 Mice

1
Department of Bioindustrial Technologies, Konkuk University, Seoul 05029, Korea
2
Center for Glocal Disease Control, KR BioTech, Seoul 05029, Korea
3
Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Korea
4
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Gwanak-gu, Seoul 08826, Korea
*
Author to whom correspondence should be addressed.
Academic Editors: Amine A. Kamen and Olivier Henry
Vaccines 2021, 9(5), 438; https://doi.org/10.3390/vaccines9050438
Received: 30 March 2021 / Revised: 26 April 2021 / Accepted: 28 April 2021 / Published: 30 April 2021
(This article belongs to the Special Issue Vectored Vaccines)
The Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family of enveloped RNA viruses. The correlation between viral infection and fetal microcephaly was revealed in 2015, yet we still lack a vaccine against ZIKV. Here, we present a genetic vaccine that delivers the premembrane (prM) and envelope (E) genes of ZIKV using a recombinant baculovirus vector that expresses a human endogenous retrovirus (HERV) envelope on its surface to enhance gene delivery. We observed that baculoviruses with HERV envelopes (AcHERV) exhibited specifically higher gene transfer efficiency in human cells compared to the wild-type baculovirus vector. Using the AcHERV baculovirus vector, we constructed a recombinant baculovirus vaccine encoding ZIKV prM/E genes (AcHERV-ZIKV), which are major targets of neutralizing antibodies. Mice immunized twice with AcHERV-ZIKV exhibited high levels of IgG, neutralizing antibodies, and IFN-γ. In challenge tests in IFN knock-out mice (A129), AcHERV-ZIKV showed complete protection in both challenge and pregnancy tests. These results suggest that AcHERV-ZIKV could be a potential vaccine candidate for human application. View Full-Text
Keywords: vaccine; ZIKV; baculovirus system; arbovirus; nonreplicated viral vector vaccine; ZIKV; baculovirus system; arbovirus; nonreplicated viral vector
Show Figures

Figure 1

MDPI and ACS Style

Choi, H.; Chun, J.; Park, M.; Kim, S.; Kim, N.; Lee, H.-J.; Kim, M.; Shin, H.Y.; Oh, Y.-K.; Kim, Y.B. The Safe Baculovirus-Based PrM/E DNA Vaccine Protected Fetuses against Zika Virus in A129 Mice. Vaccines 2021, 9, 438. https://doi.org/10.3390/vaccines9050438

AMA Style

Choi H, Chun J, Park M, Kim S, Kim N, Lee H-J, Kim M, Shin HY, Oh Y-K, Kim YB. The Safe Baculovirus-Based PrM/E DNA Vaccine Protected Fetuses against Zika Virus in A129 Mice. Vaccines. 2021; 9(5):438. https://doi.org/10.3390/vaccines9050438

Chicago/Turabian Style

Choi, Hanul, Jungmin Chun, Mina Park, Suyeon Kim, Nahyun Kim, Hee-Jung Lee, Minjee Kim, Ha Y. Shin, Yu-Kyoung Oh, and Young B. Kim. 2021. "The Safe Baculovirus-Based PrM/E DNA Vaccine Protected Fetuses against Zika Virus in A129 Mice" Vaccines 9, no. 5: 438. https://doi.org/10.3390/vaccines9050438

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop